Clinical Trials Logo

Benign Prostatic Hyperplasia clinical trials

View clinical trials related to Benign Prostatic Hyperplasia.

Filter by:

NCT ID: NCT06182189 Recruiting - Clinical trials for Benign Prostatic Hyperplasia

Protocollo N 2014 - Benign Prostatic Hyperplasia

Start date: December 1, 2014
Phase:
Study type: Observational

Prospective observational study on the quality of life of patients with BPH under medical therapy and/or undergoing surgery.

NCT ID: NCT06181175 Recruiting - Clinical trials for Benign Prostatic Hyperplasia

Treatment of BPH With CO2 Serenoa +PEA as Monotherapy or in Combination With Tamsulosin: ProSeRePEA Trial

ProSeRePEA
Start date: October 1, 2021
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the efficacy of the supplement PEAPROSTIL 600 (FARMITALIA®) composed of Serenoa Repens combined with PEA in single or combined therapy with alpha-blocker in the reduction of voiding symptoms in benign prostatic hyperplasia (BPH) patients at low risk of progression to obstructing conditioning that need for surgical therapy. Any adverse events, intolerance, allergic reactions, complications related to the products used will be recorded throughout the study period.

NCT ID: NCT06157164 Recruiting - Clinical trials for Benign Prostatic Hyperplasia

IIT-2022-Simultaneous Urolift™ and Median Lobe Enucleation

Start date: February 6, 2023
Phase:
Study type: Observational

To evaluate postoperative outcomes of BPH/Lower urinary tract symptoms, erectile function, and ejaculatory capacity of simultaneous UroLiftTM and Holmium laser enucleation of the prostatic median lobe.

NCT ID: NCT06051942 Recruiting - Clinical trials for Benign Prostatic Hyperplasia

PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

Start date: November 22, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to assess the performance and safety of the AQUABEAM Robotic System for the resection and removal of prostate tissue in patients experiencing lower urinary tract symptoms (LUTS) and are diagnosed with localized prostate cancer. Participants will go through baseline and follow up assessments up to 12 months.

NCT ID: NCT06051383 Active, not recruiting - Clinical trials for Benign Prostatic Hyperplasia

Outcome of Conducting Self-management Intervention on Severity of Lower Urinary Tract Symptoms

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

Aim of this study is to evaluate the effect of conducting self-management interventions on severity of lower urinary tract symptoms (LUTS) for patients with benign prostatic hyperplasia (BPH). Research hypothesis: To fulfill the aim of this study, the following research hypothesis was formulated: Patients with benign prostatic hyperplasia will suffer less lower urinary tract symptoms (LUTS) after conducting self-management intervention than before conducting.

NCT ID: NCT05982444 Active, not recruiting - Clinical trials for Benign Prostatic Hyperplasia

Long Term Follow up of Water Vapor Thermal Therapy (Rezum) for Benign Prostatic Hyperplasia (BPH)

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

in this study the investigators are assessing the effectiveness and morbidity of rezum therapy for benign prostatic hyperplasia by collect data and assess all patient who treated by rezum from 2 to 4 years and report these results.

NCT ID: NCT05913466 Not yet recruiting - Clinical trials for Benign Prostatic Hyperplasia

Intraprostatic Injection of Tranexamic Acid Decrease Blood Loss During Monopolar TURP

Start date: June 20, 2023
Phase: N/A
Study type: Interventional

This study aims to assess the role of intraprostatic injection of tranexamic acid in decreasing the blood loss during Transurethral resection of the prostate.

NCT ID: NCT05898932 Recruiting - Clinical trials for Benign Prostatic Hyperplasia

Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes

Start date: June 1, 2023
Phase:
Study type: Observational

The goal of this project is to use newly developed patient-reported outcomes to improve the clinical care of patients with benign prostatic hyperplasia. The use of new patient-centered tools will improve evaluation and clinical decision-making by including symptoms not commonly measured in men, such as urinary incontinence, and allow for more frequent assessment of lower urinary tract symptoms through remote surveillance. Through the use of care-coordination checklists, clinicians can be more responsive to post-treatment symptom changes, resulting in reduced bother from lower urinary tract symptoms and higher quality of life in patients with benign prostatic hyperplasia.

NCT ID: NCT05884580 Recruiting - Clinical trials for Benign Prostatic Hyperplasia

Neuflo System for the Treatment of BPH

Start date: December 2023
Phase: N/A
Study type: Interventional

The goal of this clinical study is to assess the effectiveness and safety of the Neuflo System for the treatment of benign prostatic hyperplasia (BPH). The main questions it aims to answer are: - Can treatment with the Neuflo System lead to at least a 30% improvement in lower urinary tract symptoms (LUTS) secondary to BPH, as measured by the international prostate symptom score (IPSS) at 3 months after treatment which is sustained for 12 months? - Is treatment with the Neuflo System tolerable to the patient, as measured by visual analog score (VAS) for pain before and after treatment and procedural medication requirements? - Is treatment with the Neuflo System safe, as measured by the incidence and severity of device or procedural related serious adverse events. Participants will be enrolled in the study over a 6 month period. Each participant will be treated with the Neuflo System and assessed at 3 and 12 months following treatment. A subgroup of patients will have an MRI at 1 week to assess the volume and location of ablated tissue. The duration of the study is expected to be 18 months.

NCT ID: NCT05803096 Completed - Prostate Cancer Clinical Trials

Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain

Start date: December 12, 2021
Phase: Phase 4
Study type: Interventional

Transrectal prostate biopsy is a commonly performed ambulatory procedure for diagnosing prostate cancer. Prostate biopsy are associated with pain or anxiety. Nitrous oxide (or laughing gas) is a well-known inhaled anesthetic which is frequently used in dental offices and for pediatric procedures to alleviate a patient's anxiety and pain. This study seeks to determine whether administration of nitrous oxide at the time of prostate biopsy will improve a patient's experience of care.